CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 22 enrolled
Drug / intervention
AZD2327 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00759395
NCT00759395Phase 2Completed
CompareCT.gov

An Investigation of the Antidepressant Efficacy of a Selective, High, Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder

AstraZeneca·interventional·Posted Sep 25, 2008·Updated Nov 8, 2012

In Brief

A Phase 2 clinical trial evaluating AZD2327 and Placebo for Anxious Major Depressive Disorder. Completed, enrolled 22 participants across 1 site.

Detailed Summary

This study will determine if a highly selective enkephalinergic receptor modulator is effective in the treatment of anxious major depressive disorder.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnxious Major Depressive Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 25, 2008
Enrollment StartJan 1, 2009
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 17.8 years ago

Interventions

AZD2327drug

Tablet, Oral, Daily

Placebodrug

Tablet, Oral, Daily